BUY NOW: Latest prices! Larotrectinib brings you good news

Larotrectinib is a new generation of targeted anti-cancer drugs that is unique in that it specifically targets cancer patients with TRK (neuroprimitive ectodermal tumor) gene fusions. TRKGene fusion is a rare but present genetic abnormality in some tumors. It can lead to the production of abnormal TRK protein, thereby promoting the growth and differentiation of tumor cells.

Larotrectinib has been launched in China and has not yet been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in hospitals. For specific conditions, it is recommended to consult the local hospital pharmacy. In foreign markets, larotinib has two options: original drug and generic drug. Original drugs include the German version, the American version, the European version and the Hong Kong version, and the price is about 10,000 to 20,000 yuan. In comparison, generic drugs are much cheaper. There are Lao and Bangladeshi versions of generic drugs, and the price is around two to three thousand. It is worth noting that the ingredients of original drugs and generic drugs are basically the same.

Larotrectinib blocks the growth signaling pathway of tumor cells by highly selectively inhibiting the activity of this abnormalTRK protein. This personalized treatment approach makes larotrectinib an innovative and precise treatment option. The key is that the drug's indications are mainly concentrated in patients with tumors that have TRK gene fusions, including children and adults.

Clinical study results of larotrectinib show that for patients with positive TRK gene fusion, the drug has achieved significant efficacy in the treatment of tumors, including tumor shrinkage or complete disappearance. This brings new hope for treatment for patients with this gene fusion.